NV-ALVARIA.
Today, Alvaria, Inc. is pleased to announce the successful deployment of Alvaria Cloud™ in Google Cloud Platform (GCP). Adding GCP to their current offerings of AWS and Azure expands the available public cloud options Alvaria provides to support customer experience (CX) and employee engagement (EX) strategies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220913005584/en/
Alvaria CEO, Jeff Cotten rehearses "The Modern Contact Center" for opening day at ACE 2022 where he unveils a new engagement framework, The Alvaria Enterprise Modernization Journey (Photo: Business Wire)
Providing multiple public cloud selections, including GCP, is a part of the commitment Alvaria has made to provide choice for customers in order to meet their business objectives with the proper products and services. As an enterprise CCaaS vendor, Alvaria now provides industry leading support to help enterprise brands with complex and specific configuration requirements evolved to meet the needs of rapidly evolving customer expectations.
ACE 2022, Alvaria U kicks off at 9:00 AM PDT with The Modern Contact Center, an address from Chief Executive Officer, Jeff Cotten. He will unveil a new engagement framework, The Alvaria Enterprise Modernization Journey.
“We will assist customers through a process of determining business and technology objectives, with a goal of understanding where they are today and the desired end state,” said Jeff Cotten. “We will then map the best fit of products and services that align to their business goals because with Alvaria you are not going to hear and see a one-size-fits-all approach. We aim to enable choice and flexibility.”
In addition to the CEO Address, Alvaria has a full agenda planned for former Aspect Software, Noble Systems and Alvaria customers and partners including new product demonstrations, insights from industry experts, as well as product tips and tricks and a special keynote, Customer Obsession: How to Satisfy Inherently Unsatisfiable Customers, by Gibson Biddle, Entrepreneur, Advisor, Former Netflix VP Product Management.
Core to the success of ACE each year is the participation of Alvaria Partners. Alvaria would like to thank a select group of partners who have sponsored the event: Call Design, Communik.me, CS Infocomm, ITFor, Resolutte, Rich Communication Technology, Rising Interactions and Waterfield Technologies. Furthermore, this year, Alvaria introduced the ACE Partner Certified Seller track, designed to enable Alvaria partners worldwide with tools to win business.
Alvaria SVP of Global Marketing, Colleen Sheley said, “The pandemic has greatly emphasized the need for enterprises to be resilient, secure and continue to deliver exceptional customer experiences. Brands want to invest in accelerating their consumer technology initiatives and now with the deployment of Alvaria Cloud in GCP there's now less friction and more choice than ever before.”
Registration for the virtual event is still open. Get complimentary access with code: VIRTUAL-ACE22-BEMYGUEST
To register, please visit www.alvaria.com/ace
Alvaria was founded through the merger of Aspect Software and Noble Systems. We are the world leader in enterprise-scale customer experience (CX) and workforce engagement management (WEM) solutions. Our name is derived from Latin for “hives” – nature’s perfect form for millions of years – bringing you solutions that are scalable, resilient and secure, with efficiency, speed and pinpoint accuracy. ALVARIA™. Reshaping Customer Experience™. For more information, please visit www.alvaria.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220913005584/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom